Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

John E. Levine; Bruce R. Blazar; Todd DeFor; James L M Ferrara; Daniel J. Weisdorf

doi:10.1016/j.bbmt.2008.06.013

Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

John E. Levine, Bruce R. Blazar, Todd DeFor, James L M Ferrara, Daniel J. Weisdorf

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

We previously conducted a randomized, double-blind, placebo-controlled study conducted from 2000 to 2003 of palifermin, a recombinant human keratinocyte growth factor, dosed from 240 μg/kg to 720 μg/kg, in 100 allogeneic hematopoietic stem cell transplantation (HCT) recipients. Treatment with palifermin showed beneficial effects on mucositis, but no significant effect on engraftment, acute graft-versus-host disease (GVHD), or early survival. In addition to the effect of palifermin on mucosa, other pleotrophic effects, including more rapid immune reconstitution, have been seen in experimental transplant models. Therefore, we investigated whether with longer follow-up we could detect additional differences between the palifermin-treated and placebo cohorts. We found no differences in CMV or invasive fungal infections, chronic GVHD, or long-term survival between cohorts. We conclude that the benefits of palifermin appear primarily to be limited to ameliorating mucotoxicity when given to allogeneic HCT recipients.

Original language	English (US)
Pages (from-to)	1017-1021
Number of pages	5
Journal	Biology of Blood and Marrow Transplantation
Volume	14
Issue number	9
DOIs	https://doi.org/10.1016/j.bbmt.2008.06.013
State	Published - Sep 2008

Bibliographical note

Funding Information:
The authors thank Pam James and Julie Formosa for excellent data collection and management. This work was supported by the following grants: National Institutes of Health Grants R01 HL073794, NIH P01 CA03952, and 2P30CA046592; Food and Drug Administration Grant FRD 020201; and Amgen.

Keywords

GVHD
Hematopoietic stem cell transplantation
Palifermin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.bbmt.2008.06.013

OpenUrl availability

Full text

Cite this

Levine, J. E., Blazar, B. R., DeFor, T., Ferrara, J. L. M., & Weisdorf, D. J. (2008). Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT). Biology of Blood and Marrow Transplantation, 14(9), 1017-1021. https://doi.org/10.1016/j.bbmt.2008.06.013

Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT). / Levine, John E.; Blazar, Bruce R.; DeFor, Todd et al.
In: Biology of Blood and Marrow Transplantation, Vol. 14, No. 9, 09.2008, p. 1017-1021.

Research output: Contribution to journal › Article › peer-review

Levine, JE, Blazar, BR , DeFor, T, Ferrara, JLM & Weisdorf, DJ 2008, 'Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT)', Biology of Blood and Marrow Transplantation, vol. 14, no. 9, pp. 1017-1021. https://doi.org/10.1016/j.bbmt.2008.06.013

@article{a513b12b5a67443cbd528b2294104196,

title = "Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT)",

abstract = "We previously conducted a randomized, double-blind, placebo-controlled study conducted from 2000 to 2003 of palifermin, a recombinant human keratinocyte growth factor, dosed from 240 μg/kg to 720 μg/kg, in 100 allogeneic hematopoietic stem cell transplantation (HCT) recipients. Treatment with palifermin showed beneficial effects on mucositis, but no significant effect on engraftment, acute graft-versus-host disease (GVHD), or early survival. In addition to the effect of palifermin on mucosa, other pleotrophic effects, including more rapid immune reconstitution, have been seen in experimental transplant models. Therefore, we investigated whether with longer follow-up we could detect additional differences between the palifermin-treated and placebo cohorts. We found no differences in CMV or invasive fungal infections, chronic GVHD, or long-term survival between cohorts. We conclude that the benefits of palifermin appear primarily to be limited to ameliorating mucotoxicity when given to allogeneic HCT recipients.",

keywords = "GVHD, Hematopoietic stem cell transplantation, Palifermin",

author = "Levine, {John E.} and Blazar, {Bruce R.} and Todd DeFor and Ferrara, {James L M} and Weisdorf, {Daniel J.}",

note = "Funding Information: The authors thank Pam James and Julie Formosa for excellent data collection and management. This work was supported by the following grants: National Institutes of Health Grants R01 HL073794, NIH P01 CA03952, and 2P30CA046592; Food and Drug Administration Grant FRD 020201; and Amgen. ",

year = "2008",

month = sep,

doi = "10.1016/j.bbmt.2008.06.013",

language = "English (US)",

volume = "14",

pages = "1017--1021",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

AU - Levine, John E.

AU - Blazar, Bruce R.

AU - DeFor, Todd

AU - Ferrara, James L M

AU - Weisdorf, Daniel J.

N1 - Funding Information: The authors thank Pam James and Julie Formosa for excellent data collection and management. This work was supported by the following grants: National Institutes of Health Grants R01 HL073794, NIH P01 CA03952, and 2P30CA046592; Food and Drug Administration Grant FRD 020201; and Amgen.

PY - 2008/9

Y1 - 2008/9

N2 - We previously conducted a randomized, double-blind, placebo-controlled study conducted from 2000 to 2003 of palifermin, a recombinant human keratinocyte growth factor, dosed from 240 μg/kg to 720 μg/kg, in 100 allogeneic hematopoietic stem cell transplantation (HCT) recipients. Treatment with palifermin showed beneficial effects on mucositis, but no significant effect on engraftment, acute graft-versus-host disease (GVHD), or early survival. In addition to the effect of palifermin on mucosa, other pleotrophic effects, including more rapid immune reconstitution, have been seen in experimental transplant models. Therefore, we investigated whether with longer follow-up we could detect additional differences between the palifermin-treated and placebo cohorts. We found no differences in CMV or invasive fungal infections, chronic GVHD, or long-term survival between cohorts. We conclude that the benefits of palifermin appear primarily to be limited to ameliorating mucotoxicity when given to allogeneic HCT recipients.

AB - We previously conducted a randomized, double-blind, placebo-controlled study conducted from 2000 to 2003 of palifermin, a recombinant human keratinocyte growth factor, dosed from 240 μg/kg to 720 μg/kg, in 100 allogeneic hematopoietic stem cell transplantation (HCT) recipients. Treatment with palifermin showed beneficial effects on mucositis, but no significant effect on engraftment, acute graft-versus-host disease (GVHD), or early survival. In addition to the effect of palifermin on mucosa, other pleotrophic effects, including more rapid immune reconstitution, have been seen in experimental transplant models. Therefore, we investigated whether with longer follow-up we could detect additional differences between the palifermin-treated and placebo cohorts. We found no differences in CMV or invasive fungal infections, chronic GVHD, or long-term survival between cohorts. We conclude that the benefits of palifermin appear primarily to be limited to ameliorating mucotoxicity when given to allogeneic HCT recipients.

KW - GVHD

KW - Hematopoietic stem cell transplantation

KW - Palifermin

UR - http://www.scopus.com/inward/record.url?scp=49449083795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449083795&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.06.013

DO - 10.1016/j.bbmt.2008.06.013

M3 - Article

C2 - 18721764

AN - SCOPUS:49449083795

SN - 1083-8791

VL - 14

SP - 1017

EP - 1021

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 9

ER -

Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this